Redeye maintains Orexo's valuation at SEK 80 per share. However, in this DTx update, after an overview of the US digital health investment dynamics, we build a hypothetic scenario for the valuation of Orexo, taking into account the large market potential and the generally aggressive assumptions in this space.
Follow companies at Redeye to receive the latest equity research within Life Science and Technology.
This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/